Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Miyoshi

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
BMJ Open|May 18, 2022
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)Hiroshi Nomoto, Sho Furusawa, Akinobu Nakamura, et al.
Scientific Reports|June 13, 2022
Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial functionYuki Yamauchi, Akinobu Nakamura, Takashi Yokota, et al.
Diabetes, Obesity & Metabolism|February 1, 2023
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)Yuka Takahashi, Hiroshi Nomoto, Hiroki Yokoyama, et al.
Journal of Diabetes Investigation|February 27, 2021
Glucokinase is required for high-starch diet-induced β-cell mass expansion in miceKazuhisa Tsuchida, Akinobu Nakamura, Hideaki Miyoshi, et al.
Journal of Lipid Research|October 3, 2009
Perilipin overexpression in mice protects against diet-induced obesityHideaki Miyoshi, Sandra C Souza, Mikiko Endo, et al.
Clinical Journal of Gastroenterology|July 17, 2015
A case of IgG4-related disease associated with diffuse large B cell lymphomaToshiyuki Mitsuyama, Akiyoshi Nishio, Makoto Takaoka, et al.
Journal of Diabetes Investigation|August 24, 2018
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetesKiyohiko Takahashi, Kyu Yong Cho, Akinobu Nakamura, et al.
Journal of Diabetes Investigation|December 16, 2020
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptinAika Miya, Akinobu Nakamura, Kyu Yong Cho, et al.
Endocrine Journal|November 25, 2021
Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?Hikaru Kamoshima, Hiroshi Nomoto, Kumiko Yamashita, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|May 31, 2013
A proposal of a diagnostic algorithm with validation of International Consensus Diagnostic Criteria for autoimmune pancreatitis in a Japanese cohortKimi Sumimoto, Kazushige Uchida, Toshiyuki Mitsuyama, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
BMJ Open|May 18, 2022
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)Hiroshi Nomoto, Sho Furusawa, Akinobu Nakamura, et al.
Scientific Reports|June 13, 2022
Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial functionYuki Yamauchi, Akinobu Nakamura, Takashi Yokota, et al.
Diabetes, Obesity & Metabolism|February 1, 2023
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)Yuka Takahashi, Hiroshi Nomoto, Hiroki Yokoyama, et al.
Journal of Diabetes Investigation|February 27, 2021
Glucokinase is required for high-starch diet-induced β-cell mass expansion in miceKazuhisa Tsuchida, Akinobu Nakamura, Hideaki Miyoshi, et al.
Journal of Lipid Research|October 3, 2009
Perilipin overexpression in mice protects against diet-induced obesityHideaki Miyoshi, Sandra C Souza, Mikiko Endo, et al.
Clinical Journal of Gastroenterology|July 17, 2015
A case of IgG4-related disease associated with diffuse large B cell lymphomaToshiyuki Mitsuyama, Akiyoshi Nishio, Makoto Takaoka, et al.
Journal of Diabetes Investigation|August 24, 2018
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetesKiyohiko Takahashi, Kyu Yong Cho, Akinobu Nakamura, et al.
Journal of Diabetes Investigation|December 16, 2020
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptinAika Miya, Akinobu Nakamura, Kyu Yong Cho, et al.
Endocrine Journal|November 25, 2021
Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?Hikaru Kamoshima, Hiroshi Nomoto, Kumiko Yamashita, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|May 31, 2013
A proposal of a diagnostic algorithm with validation of International Consensus Diagnostic Criteria for autoimmune pancreatitis in a Japanese cohortKimi Sumimoto, Kazushige Uchida, Toshiyuki Mitsuyama, et al.
Pageof 16